A Novel Minimally Invasive Treatment Option for Benign Prostat Hyperplasia: Intraprostatic UroLift®, The First Case Series of Turkey with Short Term Follow-up

Objective: To evaluate feasiblity, effectiveness, applicable of UroLift (R) which is a minimally invasive surgical treatment option in patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). Methods: Between March 2011 and May 2013, data of patients who were operated with UroLift (R), were investigated retrospectively. There were totally 10 patients. Demographic data of patients and internationale prostate symptom score (IPSS), quality of life (QoL) index, internationale index of erectile function (IIEF), roflowmetry (UFM) parameters were recorded before operation. Additionally, operation data, postoperative data and short follow-up were recorded and evaluated. In statistical analysis, statistical p value was accepted as p<0.05. Results: Mean age was 64.8 +/- 10 years, and 10 men evaluated totally. After 1 month and 3 months UroLift (R) implantation, in short follow-up, maximum (respectively; p<0.001, p<0.001) and mean urine flow rate statistical significant increased (respectively; p<0.001, p<0.001). Additionally post mictional residuel volume in bladder statistical significantly decreased (respectively; p=0.025, p=0.016). There was statistically significant decrease in IPSS after 1st and 3rd months of surgery (respectively, p<0.001, p<0.001). Development in QoL index were parallel to develoments in IPSS, after 1 month and 3 months of surgery (respectively; p=0.022, p=0.003). roLift (R) was effective in all patients. Additionally, there was no significant difference in IIEF scores in follow-up. Conclusion: UroLift (R) was effevtive in selected patients. In addition, it was new, safe, a novel minimally invasive surgical treatment option in BPH.